Champions Oncology Stock Earnings Reports

Champions Oncology reported Q1 FY2026 revenue of $14.0M, a rebound from Q4 softness and essentially flat year-over-year. Growth was led by the core TOS research services business with meaningful contributions from the emerging data platform. Gross margin declined to 43% from 50% a year ago, primarily due to higher outsourced costs related to radiolabeling work; management expects margin expansion as that work is brought in-house. GAAP operating loss was $0.5M, which included about $0.6M of noncash items; adjusted EBITDA was slightly positive at $60k. Operating expenses rose ~$1M, driven by deliberate investments in R&D (data platform/model depth) and sales & marketing to support the data business. Cash was $10.3M at quarter end, the company is debt-free, had positive operating cash flow (~$0.6M) and expects to be roughly cash neutral in Q2 with cash growth in H2 as revenues and margins improve. Strategic priorities highlighted: expand the data licensing business (leveraging the PDX multiomic bank), scale a radiopharmaceutical services capability (new radio license and in‑house radiochemistry), and progress Corellia (drug discovery subsidiary) with external funding support. Management tone: cautiously optimistic on macro improvements and confident in execution, while noting timing uncertainty around data deal conversions.